Navigation Links
Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
Date:9/25/2008

marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Moines, Iowa (PRWEB) October 24, 2014 ... that Perdue plans to more than double the ... 2015 in geographies supplying its soybean crush facility ... produced from this program will target several markets ... oil alternatives with good performance. , For the ...
(Date:10/25/2014)... Today, Nerium International, a leader in ... its “Reflect Your Youth” contest, an effort launched to ... difference in their skin since using Nerium’s product line, ... life as a result of their newfound confidence. , ... by Nerium International to inspire conversations focused on the ...
(Date:10/25/2014)... MA (PRWEB) October 25, 2014 ... products, is pleased to announce the release of ... the highest level of contamination containment in critical ... Class 3 and higher cleanroom environments, ValuSeal® IonX™ ... polyester knit laundered wiper that continues Berkshire’s innovative ...
(Date:10/25/2014)... Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today ... on Thymosins in Health and Disease in ... beta 4 (TB4) linked with rhodamine (a fluorescent tracer ... rodent model of stroke, it was visualized outside of ... tissue of the brain).   The leakage of TB4 in ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... CYT) announced that it will present data on its ... 100th Annual Meeting of the American Association for Cancer ... Scientist at Cytopia, will be presenting the poster in ... poster session on Tuesday, April 21, 2009 from ...
... is the establishment of The Waters Centre for BioMedical ... Waters Corporation (NYSE: WAT ) and ... England, today signed a collaborative research agreement intended to ... spectrometry (MS) technologies, including Waters(R) SYNAPT High Definition MS(TM) ...
... 15 inVentiv Health, Inc. (Nasdaq: VTIV ) ... results and conduct a conference call on Friday, May 8, ... , To listen, please dial 800-358-8448 (Domestic) or ... live on the Internet at http://www.inventivhealth.com/about_us/n_webcasts.aspx ...
Cached Biology Technology:Cytopia Presentation on VDA CYT997 at AACR Conference 2Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies 2Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies 3inVentiv Health to Announce First Quarter 2009 Results and Conduct Conference Call on Friday, May 8 2
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2
... Forest Service researchers found that site fidelity, the tendency ... the Sierra Nevada yellow-legged frog. Research showed how the ... trout are negatively impacting the habitat of a species ... and will further stress frogs with strong site fidelity. ...
... are fine, but seeing is believing. That,s the thought behind ... put to the test calculations made more than a century ... came up with an elegant set of equations to describe ... The theory has been a touchstone ever since for researchers ...
... green algae to produce hydrocarbon oil for biofuel production is ... millions of years, according a Texas AgriLife Research scientist. ... be readily detected in petroleum deposits and coal deposits suggesting ... developing these deposits and may be the major contributor," said ...
Cached Biology News:Sierra Nevada yellow-legged frog's site fidelity may lead to further decline 2Look at Mie! 2AgriLife scientists do groundwork for genetic mapping of algae biofuel species 2AgriLife scientists do groundwork for genetic mapping of algae biofuel species 3
... Perhaps sheer in-house demand is causing shortages ... your precious antibody. This can cause unwanted ... • Receive royalties for your hard work ... let us build it up and market ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
... virus is a type I eukaryotic topoisomerase ... turns (also called right- and left-handed supercoils) ... the reaction is a covalently closed, circular ... turns. DNA Topoisomerase I does not absolutely ...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: